Literature DB >> 25313234

Emerging techniques and technologies in brain tumor imaging.

Benjamin M Ellingson1, Martin Bendszus1, A Gregory Sorensen1, Whitney B Pope1.   

Abstract

The purpose of this report is to describe the state of imaging techniques and technologies for detecting response of brain tumors to treatment in the setting of multicenter clinical trials. Within currently used technologies, implementation of standardized image acquisition and the use of volumetric estimates and subtraction maps are likely to help to improve tumor visualization, delineation, and quantification. Upon further development, refinement, and standardization, imaging technologies such as diffusion and perfusion MRI and amino acid PET may contribute to the detection of tumor response to treatment, particularly in specific treatment settings. Over the next few years, new technologies such as 2(3)Na MRI and CEST imaging technologies will be explored for their use in expanding the ability to quantitatively image tumor response to therapies in a clinical trial setting.
© The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  MRI; PET; T1 subtraction; brain tumors; diffusion MRI; imaging biomarker; perfusion MRI; response assessment

Mesh:

Year:  2014        PMID: 25313234      PMCID: PMC4195527          DOI: 10.1093/neuonc/nou221

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  95 in total

1.  Perfusion imaging with NMR contrast agents.

Authors:  B R Rosen; J W Belliveau; J M Vevea; T J Brady
Journal:  Magn Reson Med       Date:  1990-05       Impact factor: 4.668

2.  Subtracted synthetic images in Gd-DTPA enhanced MR.

Authors:  Y Suto; B E Caner; Y Tamagawa; T Matsuda; I Kimura; H Kimura; T Toyama; Y Ishii
Journal:  J Comput Assist Tomogr       Date:  1989 Sep-Oct       Impact factor: 1.826

3.  Measuring masses on cross-sectional images.

Authors:  B D Fornage
Journal:  Radiology       Date:  1993-04       Impact factor: 11.105

Review 4.  Tissue specific perfusion imaging using arterial spin labeling.

Authors:  J A Detre; W Zhang; D A Roberts; A C Silva; D S Williams; D J Grandis; A P Koretsky; J S Leigh
Journal:  NMR Biomed       Date:  1994-03       Impact factor: 4.044

5.  Intracellular concentration of sodium and other elements as related to mitogenesis and oncogenesis in vivo.

Authors:  I L Cameron; N K Smith; T B Pool; R L Sparks
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

6.  Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography.

Authors:  G Di Chiro; R L DeLaPaz; R A Brooks; L Sokoloff; P L Kornblith; B H Smith; N J Patronas; C V Kufta; R M Kessler; G S Johnston; R G Manning; A P Wolf
Journal:  Neurology       Date:  1982-12       Impact factor: 9.910

Review 7.  Glutamine and cancer.

Authors:  W W Souba
Journal:  Ann Surg       Date:  1993-12       Impact factor: 12.969

8.  Subtraction gadolinium enhanced magnetic resonance for head and neck imaging.

Authors:  G A Lloyd; P G Barker; P D Phelps
Journal:  Br J Radiol       Date:  1993-01       Impact factor: 3.039

9.  Dynamic study of supratentorial gliomas with L-methyl-11C-methionine and positron emission tomography.

Authors:  A Lilja; K Bergström; P Hartvig; B Spännare; C Halldin; H Lundqvist; B Långstrom
Journal:  AJNR Am J Neuroradiol       Date:  1985 Jul-Aug       Impact factor: 3.825

10.  Studies in variation associated with the measurement of solid tumors.

Authors:  P T Lavin; G Flowerdew
Journal:  Cancer       Date:  1980-09-01       Impact factor: 6.860

View more
  16 in total

Review 1.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Authors:  Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

2.  Reproducibility of dynamic contrast-enhanced MRI and dynamic susceptibility contrast MRI in the study of brain gliomas: a comparison of data obtained using different commercial software.

Authors:  Gian Marco Conte; Antonella Castellano; Luisa Altabella; Antonella Iadanza; Marcello Cadioli; Andrea Falini; Nicoletta Anzalone
Journal:  Radiol Med       Date:  2017-01-09       Impact factor: 3.469

3.  Comparison of T1 mapping and fixed T1 method for dynamic contrast-enhanced MRI perfusion in brain gliomas.

Authors:  G M Conte; L Altabella; A Castellano; V Cuccarini; A Bizzi; M Grimaldi; A Costa; M Caulo; A Falini; N Anzalone
Journal:  Eur Radiol       Date:  2019-04-10       Impact factor: 5.315

4.  Tumour heterogeneity in glioblastoma assessed by MRI texture analysis: a potential marker of survival.

Authors:  David Molina; Julián Pérez-Beteta; Belén Luque; Elena Arregui; Manuel Calvo; José M Borrás; Carlos López; Juan Martino; Carlos Velasquez; Beatriz Asenjo; Manuel Benavides; Ismael Herruzo; Alicia Martínez-González; Luis Pérez-Romasanta; Estanislao Arana; Víctor M Pérez-García
Journal:  Br J Radiol       Date:  2016-06-20       Impact factor: 3.039

5.  Consensus recommendations on standardized magnetic resonance imaging protocols for multicenter canine brain tumor clinical trials.

Authors:  Rebecca A Packer; John H Rossmeisl; Michael S Kent; John F Griffin; Christina Mazcko; Amy K LeBlanc
Journal:  Vet Radiol Ultrasound       Date:  2018-03-09       Impact factor: 1.363

Review 6.  Response Assessment in Neuro-Oncology Clinical Trials.

Authors:  Patrick Y Wen; Susan M Chang; Martin J Van den Bent; Michael A Vogelbaum; David R Macdonald; Eudocia Q Lee
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

7.  Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib.

Authors:  Benjamin M Ellingson; Grace Hyun J Kim; Matt Brown; Jihey Lee; Noriko Salamon; Lori Steelman; Islam Hassan; Shuchi S Pandya; Saewon Chun; Michael Linetsky; Bryan Yoo; Patrick Y Wen; Ingo K Mellinghoff; Jonathan Goldin; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

Review 8.  Treating recurrent glioblastoma: an update.

Authors:  Carlos Kamiya-Matsuoka; Mark R Gilbert
Journal:  CNS Oncol       Date:  2015

9.  T1-weighted and T2-weighted Subtraction MR Images for Glioma Visualization and Grading.

Authors:  Mohammed Goryawala; Bhaswati Roy; Rakesh K Gupta; Andrew A Maudsley
Journal:  J Neuroimaging       Date:  2020-11-30       Impact factor: 2.324

10.  A data-driven statistical model that estimates measurement uncertainty improves interpretation of ADC reproducibility: a multi-site study of liver metastases.

Authors:  Ryan Pathak; Hossein Ragheb; Neil A Thacker; David M Morris; Houshang Amiri; Joost Kuijer; Nandita M deSouza; Arend Heerschap; Alan Jackson
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.